Clinical prognosis analysis of extracorporeal membrane oxygenation in patients with heart transplantation

Xiaozu Liao (liaoxiaozu@163.com)  
Sun Yat-Sen University  
https://orcid.org/0000-0002-5727-901X

Zhou Cheng  
Sun Yat-Sen University

Liqiang Wang  
Sun Yat-Sen University

Binfei Li  
Sun Yat-Sen University

Weizhao Huang  
Sun Yat-Sen University

Hongyu Ye  
Sun Yat-Sen University

Haiming Jiang  
Sun Yat-Sen University

Zhanyuan Zhao  
Sun Yat-Sen University

Yong Yuan  
Sun Yat-Sen University

Research article

Keywords: Heart transplantation; extracorporeal membrane oxygenation; clinical prognosis

Posted Date: May 7th, 2019

DOI: https://doi.org/10.21203/rs.2.9490/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published at Herz on August 13th, 2019. See the published version at https://doi.org/10.1007/s00059-019-04843-9.
Abstract

Purpose Extracorporeal membrane oxygenation (ECMO) is the primary indication for transplanted right heart failure in transition and postoperative period for heart transplantation patients. This study explored risk factors affecting the clinical prognosis of ECMO through analyzing the clinical data of heart transplantation patients with such condition. Methods Data on 28 heart transplantation patients with ECMO obtained from January 2012 to January 2018 in the People’s Hospital of Zhongshan City were retrospectively analyzed. Results A total of 25 patients (20 male and 5 female) were included in this study. Heart transplantation among patients was performed mainly due to cardiomyopathy (77.8%). Eighteen patients survived and were discharged 18 (72%). Four patients were treated with cardiopulmonary resuscitation before ECMO, and three patients died in the hospital. No differences existed among the surviving and death group donors (N-terminal pro b-type natriuretic peptide[NT-proBNP], creatine kinase-muscle/brain[CK-MB], warm ischemia time of donated heart, cold ischemia time of donated heart, total ischemia time of donated heart, and donator type). Univariate analysis showed that body mass index(BMI), length of stay in intensive care unit(ICU), and cardiopulmonary resuscitation are relevant prognosis factors in applying ECMO for patients with heart transplantation. Multi-factor logistic regression results show that cardiopulmonary resuscitation before ECMO (OR: 49.45, 95% CI[1.37, 1781.6]; P=0.033) is an independent risk factor influencing prognosis. Conclusion ECMO is an important life support method for patients with heart transplantation before and after the operation. Patients with obesity, poor preoperative cardiac function, and considerable red blood cell transfusions during surgery may influence the prognosis of patients. Extracardiac compression before ECMO of patients is an independent risk factor for their prognosis.

Background

Heart transplantation is the last choice for cardiac patients at the end phase[1]. Extracorporeal membrane oxygenation (ECMO) is an important choice for patients with refractory cardiogenic shock, and it has been widely used in cardiogenic shock resulting from various factors, such as explosive myocardial inflammation, myocardial infarct, low cardiac output after cardiac surgery, and heart transplantation transition[2-5]. ECMO is also the main auxiliary support for transplant failure after heart transplantation[6]. Among the related factors, transplanted right heart failure caused by severe pulmonary vascular disease secondary to pulmonary hypertension is the main indication of ECMO. Previous research indicate that high simplified acute physiology score II before ECMO, diabetic mellitus history, and thrombocytopenia are risk factors of prognosis of patients assisted with ECMO[6-8]. However, limited reports focused on patient prognosis analysis assisted with ECMO. This study analyzed the clinical data of patients with heart transplantation applying ECMO in one center to explore its prognosis risk factors.

Materials And Methods

1.1 Patient choice retrospective
Analysis of 28 heart transplantation patients with EMCO was conducted from January 2012 to January 2018 in the People's Hospital of Zhongshan City. Inspection and approval were sought from the ethics committee of the People's Hospital of Zhongshan City. Excluded patients comprised those who are younger than 18 years old. Finally, 25 patients whose ECMO-assisted time was less than 48 h were included in the study.

1.2 ECMO method

ECMO indications consist of the following: patients exhibiting tissue hypoperfusion performance and hypotension and low cardiac output requiring adequate blood volume; appropriate volume management, positive inotropic drugs, and vasoconstriction or intra-aortic balloon pump application for shock still in use; pulmonary hypertension, decreased right heart function, failed medication, and sustained shock in continual progress. The perfusion system comprised a Medtronic Biopump centrifugal pump, Medtronic oxygenator, ECMO set filled with Cameda heparin provided by Medtronic, and whole Medtronic intubate of femoral artery and vein, whose size is determined by the patient's weight, height, and blood vessel thickness. All patients were treated with vein-arterial ECMO (vein-artery ECMO,V-AECMO) mode. Medtronic heparin-coated integral femoral arteriovenous intubate was placed separately through the femoral artery and vein 15 Fr-20 Fr (10–15 cm) and 19 Fr–22 Fr (35–45 cm). The distal extremity of the arterial intubate was placed in a reperfusion catheter, 6 Fr–8 Fr cannula, and connected to the femoral cannula shunt joint.

1.3 Data collection

The general condition of the patient before heart transplantation was collected, with the specific information shown in Table 1. Table 3 shows in detail the condition of patients with heart transplantation. After heart transplantation, ECMO was applied; the specific data are shown in Table 4. Table 2 provides specific information on donor status.

1.4 Statistics Analysis

SPSS2.0 software was adopted in this study, and variance was expressed by the mean ± standard deviation if the measurement data satisfied normal distribution. The comparison between groups was based on independent sample t test. Otherwise, the median (interquartile range) was used, and independent sample nonparametric rank-sum test was used for comparison between groups. The counting data were expressed as percentages, and chi-square test was used for comparison between groups. The influencing factors of the outcomes of exploration were analyzed by multivariate logistic regression analysis, and a \( P \) value of <0.05 was considered statistically significant.

Results

2.1 Basic conditions and clinical prognosis of patients
A total of 25 patients (20 male and 5 female) were included in this study. Heart transplantation was performed mainly due to cardiomyopathy (77.8%). Eighteen patients survived and were discharged (72%). Four patients were treated with cardiopulmonary resuscitation before ECMO, and three patients died in the hospital (Table 1).

2.2 Donator status

Table 2 shows the donator status of the two groups for patients. No differences existed in the two donor groups (N-terminal pro b-type natriuretic peptide (NT-proBNP), creatine kinase-muscle/brain (CK-MB), warm ischemia time of donated heart, cold ischemia time of donated heart, total ischemia time of donated heart, and donator type).

2.3 Univariate analysis of ECMO prognosis for patients with heart transplantation

Univariate analysis showed that body mass index (BMI), days of stay in intensive care unit (ICU), and cardiopulmonary resuscitation are relevant prognosis factors in applying ECMO for patients with heart transplantation (Tables 1 and 4).

2.4 Multi-factor logistic regression analysis of ECMO for prognosis of patients with heart transplantation

Multi-factor logistic regression results showed that cardiopulmonary resuscitation before ECMO (odds ratio (OR): 49.45; 95% confidence interval (C.I.): [1.37, 1781.6]; P=0.033) is an independent risk factor influencing prognosis (Table 5).

Discussion

ECMO is an important choice for patients with refractory cardiogenic shock and can be used in waiting for heart transplant patients and heart failure after heart transplantation. This study aimed at exploring risk factors affecting the clinical prognosis through analyzing the clinical data of heart transplantation patients with ECMO. The results of this study indicate that ECMO-assisted survival rate of heart transplant patients reaches 72%. Univariate analysis showed that high BMI, high NT-proBNP before operation, substantial erythrocyte infusion, and long period of stay in ICU are prognosis risk factors for patients with heart transplantation. Univariate analysis indicates that CPR before ECMO of a patient is an independent risk factor for prognosis.

The single factors in this study suggest that higher BMI leads to poorer prognosis, which may be related to the inability of obese patients to achieve adequate blood flow. However, the research of SALNA et al. indicated that survival discharge rates of obese patients and morbidly obese patients showed no statistical difference from that of non-obese patients assisted by ECMO. Thus, BMI is not an analysis factor predicting the prognosis of patients in hospitals [9]. Furthermore, research results of Lee et al, who showed the increased death rate of patients with high BMI and assisted by ECMO in 30 days, are the same with those of this research [10]. Hospital-acquired infection is one of the complications of ECMO,
thus increasing postoperative mortality \cite{11}. Long-term stay in ICU is the main risk factor for all nosocomial infections \cite{12}. This study demonstrates that long-term stays in ICU are risk factors for the prognosis of heart transplantation patients. The use of postoperative immunosuppressive agents in heart transplant patients may increase the risk of infection in patients.

This study demonstrates that CPR before ECMO prognosis is an independent risk factor for prognosis. Studies have shown that rapid ECMO assist after cardiac arrest is an important factor in reducing neurological complications \cite{13}, whereas long-term CPR will increase patient mortality \cite{14}. Establishing ECMO in a timely manner after cardiac arrest affects the patient's prognosis \cite{15}. Therefore, the reasons for the results of this study may include the following: 1. The quality of cardiopulmonary resuscitation and inadequate extracardiac and untimely compression, which lead to insufficient infusion of tissue and organs, result in hypoxia and necrosis of tissue and organs and ultimately affect prognosis. Lactic acid is an important indicator of metabolism. Studies have shown that hyperlactosis is an independent risk factor affecting the prognosis of patients \cite{16}. 2. Critical patient condition is and poor general condition. In this study, patients with heart transplantation included those with valvular disease, cardiomyopathy, or coronary heart disease, featuring poor heart function. Decreased cardiac reserve can easily lead to heart failure and final cardiac arrest. These patients may suffer from impaired function of tissues and organs, such as liver and kidney. The occurrence of cardiac arrest further impairs their function. The sustained hyperbilirubin affects the prognosis of patients \cite{17}.

This study features limitations: 1. The study is a single-center retrospective study; 2. the study sample size is small; 3. variables such as complications are unaffected by factors such as small sample size. A multi-center joint study will be conducted in the future to expand the sample size and analytical variables.

**Conclusion**

ECMO is an important life support method for patients with heart transplantation before and after the operation. Patients with obesity, poor preoperative cardiac function, and sizeable red blood cell transfusions during surgery may influence the prognosis of patients. Extracardiac compression before ECMO of the patients is an independent risk factor for the prognosis of patients.

**List Of Abbreviations**

Extracorporeal membrane oxygenation : ECMO;

terminal pro b-type natriuretic peptide : NT-proBNP;

Creatine kinase-muscle/brain : CK-MB;

**Declarations**
ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Retrospective data collection was approved by the Institutional Review Board at Zhongshan hospital affiliated to Sun Yat-Sen University.

CONSENT FOR PUBLICATION

WRITTEN INFORMED CONSENT FOR PUBLICATION WAS OBTAINED FROM ALL PARTICIPANTS

AVAILABILITY OF DATA AND MATERIAL

ALL DATA GENERATED OR ANALYSED DURING THIS STUDY ARE INCLUDED IN THIS PUBLISHED ARTICLE

COMPETING INTERESTS

NO CONFLICT OF INTEREST EXISTS IN THE SUBMISSION OF THIS MANUSCRIPT.

FUNDING

NO FUNDING

AUTHORS’ CONTRIBUTIONS

Xiaozu Liao • DRAFTING ARTICLE
Zhou Cheng • DATA COLLECTION
Liqiang Wang • DATA ANALYSIS
Binfei Li • DESIGN
Weizhao Huang • DATA ANALYSIS
Hongyu Ye • DATA ANALYSIS
Haiming Jiang • CRITICAL REVISION OF ARTICLE
Zhanyuan Zhao • STATISTICS
Yong Yuan • CRITICAL REVISION OF ARTICLE

ACKNOWLEDGEMENTS

NO

References
1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J.* 2016; 37(27):2129-2200.

[2] Sawamura A, Okumura T, Hirakawa A, et al. Early Prediction Model for Successful Bridge to Recovery in Patients With Fulminant Myocarditis Supported With Percutaneous Venoarterial Extracorporeal Membrane Oxygenation - Insights From the CHANGE PUMP Study. [J]. Circulation Journal Official Journal of the Japanese Circulation Society, 2017, 23(10):S16.

[3] Pabst D1, Foy AJ, Peterson B, Soleimani B, Brehm CE. Predicting Survival in Patients Treated With Extracorporeal Membrane Oxygenation After Myocardial Infarction. Crit Care Med. 2018 Jan 25.

[4] Dobrilovic N, Lateef O, Michalak L, et al. Extracorporeal Membrane Oxygenation Bridges Inoperable Patients to Definitive Cardiac Operation. [J]. Asaio Journal, 2017:1.

[5] Fukuhara S, Takeda K, Kurlansky PA, et al. Extracorporeal membrane oxygenation as a direct bridge to heart transplantation in adults. [J]. Journal of Thoracic & Cardiovascular Surgery, 2017.

Santise G, Panarello G, Ruperto C, et al. Extracorporeal membrane oxygenation for graft failure after heart transplantation: a multidisciplinary approach to maximize weaning rate. *Int J Artif Organs.* 2014;37(9):706-714.

Lee S H, Shin D S, Kim J R, et al. Factors associated with mortality risk in critical care patients treated with veno-arterial extracorporeal membrane oxygenation. [J]. Heart & Lung the Journal of Critical Care, 2017, 46(3):137.

Opfermann P, Bevilacqua M, Felli A, et al. Prognostic Impact of Persistent Thrombocytopenia During Extracorporeal Membrane Oxygenation: A Retrospective Analysis of Prospectively Collected Data From a Cohort of Patients With Left Ventricular Dysfunction After Cardiac Surgery. [J]. Critical Care Medicine, 2016, 44(12):1.

Salna M, Chicotka S, Agerstrand C, et al. Morbid obesity is not a contraindication to transport on extracorporeal support. [J]. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2017, 53(4).

Lee W C, Fang C Y, Chen H C, et al. Associations with 30-day survival following extracorporeal membrane oxygenation in patients with acute ST segment elevation myocardial infarction and profound cardiogenic shock. [J]. Heart & Lung the Journal of Critical Care, 2016, 45(6):532-537.

Hei Feilong, Long Cun, Yu Kun. The study of Extracorporeal membrane oxygenation complications. [J]. Chinese journal of extracorporeal circulation, 2005, 3 (4) : 243-245.
[12] Oztoprak N, Cevik M A, Akinci E, et al. Risk factors for ICU-acquired methicillin-resistant Staphylococcus aureus infections[J]. American Journal of Infection Control, 2006, 34(1):1-5.

[13] Yukawa T, Kashiura M, Sugiyama K, et al. Neurological outcomes and duration from cardiac arrest to the initiation of extracorporeal membrane oxygenation in patients with out-of-hospital cardiac arrest: a retrospective study. [J]. Scandinavian Journal of Trauma Resuscitation & Emergency Medicine, 2017, 25(1):95.

[14] Morris M C, Wernovsky G, Nadkarni V M. Survival outcomes after extracorporeal cardiopulmonary resuscitation instituted during active chest compressions following refractory in-hospital pediatric cardiac arrest[J]. Pediatr Crit Care Med, 2004, 5(5):440-446.

[15] Chen Y S, Chao A, Yu H Y, et al. Analysis and results of prolonged resuscitation in cardiac arrest patients rescued by extracorporeal membrane oxygenation[J]. Journal of the American College of Cardiology, 2003, 41(2):197-203.

[16] Omar H R, Mirsaedi M, Shumac J, et al. Incidence and predictors of ischemic cerebrovascular stroke among patients on extracorporeal membrane oxygenation support[J]. Journal of Critical Care, 2015, 32:48.

[17] Freundt M, Lunz D, Philipp A, et al. Impact of dynamic changes of elevated bilirubin on survival in patients on veno-arterial extracorporeal life support for acute circulatory failure[J]. Plos One, 2017, 12(10):e0184995.

**Tables**

Table 1 General conditions before heart transplantation in two groups of patients
| Variable                          | Grouping       | Discharge (18) | Death (7) | chi-square/t value | P value |
|----------------------------------|----------------|----------------|-----------|--------------------|---------|
| Gender                           | Male           | 14 (77.8%)     | 6 (85.7%) | 0.198              | 0.656   |
|                                  | Female         | 4 (22.2%)      | 1 (14.3%) |                    |         |
| Age                              |                | 42.44±14.09    | 46.86±17.83 |                   | 0.520   |
| BMI                              |                | 19.67±4.64     | 25.71±9.39 | -2.172             | 0.040   |
| ABO blood group                   | A              | 4 (22.2%)      | 1 (14.3%) | 0.289              | 0.866   |
|                                  | B              | 6 (33.3%)      | 3 (42.9%) |                    |         |
|                                  | O              | 8 (44.4%)      | 3 (42.9%) |                    |         |
| Smoking                          | Non-smoking    | 14 (77.8%)     | 7 (100.0%)| 1.852              | 0.174   |
|                                  | Smoking        | 4 (22.2%)      | 0 (0.0%)  |                    |         |
| Etiological diagnosis            | Valvular disease| 3 (16.7%)     | 2 (28.6%) | 0.773              | 0.680   |
|                                  | Coronary heart disease| 1 (5.6%) | 0 (0.0%) |               |         |
|                                  | Myocardiopathy | 14 (77.8%)     | 5 (71.4%) |                   |         |
| Heart function classification    | III            | 5 (27.8%)      | 1 (14.3%) | 0.503              | 0.478   |
|                                  | IV             | 13 (72.2%)     | 6 (85.7%) |                   |         |
| Diabetes mellitus                | No             | 17 (94.4%)     | 5 (71.4%) | 2.528              | 0.112   |
|                                  | Yes            | 1 (5.6%)       | 2 (28.6%) |                    |         |
| CPR before ECMO                  | No             | 17 (94.4%)     | 4 (57.1%) | 5.218              | 0.022   |
|                                  | Yes            | 1 (5.6%)       | 3 (42.9%) |                    |         |
| Active drugs for vein vascular application | No | 12 (66.7%) | 3 (42.9%) | 1.190 | 0.275 |
|                                  | Yes            | 6 (33.3%)      | 4 (57.1%) |                    |         |
| ECMO applied before operation    | No             | 16 (88.9%)     | 4 (57.1%) | 3.175              | 0.075   |
|                                  | Yes            | 2 (11.1%)      | 3 (42.9%) |                    |         |
| Preoperation creatinine          |                | 102.09±60.77   | 119.86±59.42 | -0.660             | 0.516   |
| Preoperation glutamic–oxaloacetic transaminase AST | | 27.00 (16.00, 50.75) | 67.00 (12.00, 166.00) | -0.576 | 0.565 |
Preoperation ALT | 24.00 (16.75, 47.75) | 77.00 (21.00, 86.00) | -1.241 | 0.215
Preoperation bilirubin | 25.10 (17.35, 34.85) | 32.90 (24.20, 89.00) | -1.513 | 0.130
Preoperation NT-proBNP | 114.50 (89.00, 163.75) | 754.10 (120.00, 8900.00) | -2.064 | 0.039
Left ventricular ejection fraction | 31.50±17.98 | 30.57±16.97 | 0.118 | 0.907
Estimated pulmonary systolic pressure | 56.39±18.38 | 56.13±17.65 | 0.033 | 0.974

cardiopulmonary resuscitation: CPR

**Table 2 Donor status of two groups of patients**

| Variable          | Grouping         | discharge | death         | chi-square/t value | P value |
|-------------------|------------------|-----------|---------------|--------------------|---------|
| NT-proBNP         |                  | 86.72±32.34 | 77.29±15.00   | 0.735               | 0.470   |
| CK-MB             |                  | 16.56±9.75  | 13.00±3.16    | 0.935               | 0.360   |
| Warm ischemia time|                  | 3.67±1.14   | 3.57±0.79     | 0.202               | 0.842   |
| Cold ischemia time|                  | 176.67±94.53 | 163.29±55.97 | 0.349               | 0.730   |
| Total ischemia time|                | 180.33±94.54 | 167.29±55.88 | 0.340               | 0.737   |
| Donor type        | cerebral death   | 13(72.2%)   | 5(71.4%)      | 0.002               | 0.968   |
|                   | Total            | 5(27.8%)    | 2(28.6%)      |                     |         |

**Table 3 Conditions during heart transplantation operation in two groups of patients**
| Variable                          | Grouping                  | discharge       | death            | chi-square/t value | P value |
|----------------------------------|---------------------------|-----------------|------------------|--------------------|---------|
| Extracorporeal circulation time  |                           | 187.06±70.56    | 229.71±52.49     | -1.444             | 0.162   |
| Clamping time of ascending aorta|                           | 106.00±42.31    | 133.86±34.58     | -1.547             | 0.136   |
| Erythrocyte                      |                           | 200.00 (0.00,   | 1200.00 (800.00, 1400.00) | -2.260             | 0.024   |
|                                 |                           | 850.00)         |                  |                    |         |
|                                 |                           | 600.00 (0.00,   | 800.00 (500.00, 1200.00) | -1.425             | 0.154   |
|                                 |                           | 800.00)         |                  |                    |         |
| Platelet                         |                           | 0.00 (0.00, 62.50) | 250.00 (0.00, 500.00) | -1.617             | 0.106   |

Table 4 Application of ECMO in two groups of patients after operation

| Variable                          | Grouping                  | discharge       | death            | chi-square/t value | P value |
|----------------------------------|---------------------------|-----------------|------------------|--------------------|---------|
| Days stayed in ICU               | 8.00 (6.00, 11.75)        | 19.00 (15.00, 23.00) | -3.006           | 0.003               |
| Total time of mechanical ventilation | 56.50 (25.75, 184.00)    | 240.00 (25.00, 480.00) | -1.182           | 0.237               |
| Total application time of ECMO   | 106.00 (83.00, 133.50)    | 120.00 (72.00, 230.00) | -0.182           | 0.856               |
| Postoperation input of packed erythrocyte | 1300.00 (0.00, 3750.00) | 4000.00 (0.00, 8000.00) | -0.801           | 0.423               |
| Postoperation input of plasma    | 1400.00 (0.00, 4825.00)   | 3000.00 (0.00, 4000.00) | -0.344           | 0.731               |
| Postoperation input of platelet concentrates | 135.00 (0.00, 762.50) | 500.00 (0.00, 500.00) | -0.501           | 0.616               |
| Multiple cardiopulmonary bypass  | No                        | 18 (100.0%)     | 6 (85.7%)        | 2.679              | 0.102   |
|                                  | Yes                       | 0 (0.0%)        | 1 (14.3%)        |                    |         |
| Secondary chest open             | No                        | 9 (50.0%)       | 2 (28.6%)        | 0.939              | 0.332   |
|                                  | Yes                       | 9 (50.0%)       | 5 (71.4%)        |                    |         |
| Infection site                   | Pulmonary infection       | 9 (50.0%)       | 5 (71.4%)        | 0.939              | 0.332   |
|                                  | No                        | 9 (50.0%)       | 2 (28.6%)        |                    |         |
Table 5: Multivariate logistic regression analysis results

| Variable                  | B     | S.E. | Wals | P value | OR value | 95% of OR value C.I. | lower limit | upper limit |
|---------------------------|-------|------|------|---------|-----------|----------------------|-------------|-------------|
|                           |       |      |      |         |           |                      |             |             |
| BMI                       | 0.333 | 0.172 | 3.760 | 0.053   | 1.396     | 0.996                | 1.955       |
| Days stayed in ICU        | 0.151 | 0.084 | 3.279 | 0.070   | 1.163     | 0.988                | 1.370       |
| CPR before ECMO           | 3.901 | 1.829 | 4.551 | 0.033   | 49.458    | 1.373                | 1781.663    |